Biltmore Family Office’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.18M Sell
3,264
-188
-5% -$64.4K 0.16% 98
2026
Q1
$1.21M Buy
3,452
+376
+12% +$134K 0.17% 92
2025
Q4
$1.01M Buy
3,076
+508
+20% +$161K 0.14% 101
2025
Q3
$725K Buy
2,568
+193
+8% +$56K 0.1% 116
2025
Q2
$663K Sell
2,375
-368
-13% -$104K 0.11% 108
2025
Q1
$855K Sell
2,743
-38
-1% -$11.2K 0.15% 96
2024
Q4
$725K Sell
2,781
-243
-8% -$72.1K 0.12% 99
2024
Q3
$974K Buy
3,024
+133
+5% +$43.5K 0.17% 86
2024
Q2
$903K Buy
2,891
+600
+26% +$176K 0.17% 85
2024
Q1
$651K Sell
2,291
-42
-2% -$12.3K 0.13% 96
2023
Q4
$672K Hold
2,333
0.14% 95
2023
Q3
$627K Hold
2,333
0.14% 99
2023
Q2
$518K Buy
2,333
+737
+46% +$171K 0.11% 106
2023
Q1
$386K Buy
1,596
+49
+3% +$12K 0.08% 157
2022
Q4
$406K Sell
1,547
-58
-4% -$15.5K 0.08% 150
2022
Q3
$362K Sell
1,605
-122
-7% -$29.6K 0.08% 123
2022
Q2
$420K Sell
1,727
-250
-13% -$61.3K 0.1% 120
2022
Q1
$478K Sell
1,977
-166
-8% -$38.1K 0.1% 110
2021
Q4
$482K Buy
2,143
+416
+24% +$87.8K 0.09% 128
2021
Q3
$367K Hold
1,727
0.09% 132
2021
Q2
$421K Sell
1,727
-105
-6% -$25.8K 0.12% 118
2021
Q1
$456K Sell
1,832
-1,000
-35% -$239K 0.14% 99
2020
Q4
$651K Buy
2,832
+190
+7% +$43.8K 0.2% 75
2020
Q3
$671K Hold
2,642
0.37% 61
2020
Q2
$623K Hold
2,642
0.38% 68
2020
Q1
$536K Sell
2,642
-77
-3% -$16.8K 0.35% 76
2019
Q4
$655K Buy
2,719
+77
+3% +$17K 0.26% 81
2019
Q3
$511K Buy
2,642
+952
+56% +$183K 0.22% 90
2019
Q2
$311K Sell
1,690
-70
-4% -$12.5K 0.17% 108
2019
Q1
$334K Hold
1,760
0.17% 112
2018
Q4
$343K Buy
1,760
+48
+3% +$9.36K 0.19% 108
2018
Q3
$355K Hold
1,712
0.17% 112
2018
Q2
$316K Sell
1,712
-975
-36% -$172K 0.16% 112
2018
Q1
$458K Buy
2,687
+870
+48% +$160K 0.2% 105
2017
Q4
$316K Buy
+1,817
New +$322K 0.14% 120

Other funds holding AMGN

Biltmore Family Office's AMGN Position: Q2 2026 in Review

Biltmore Family Office reduced its Amgen (AMGN) stake by 5.4% in Q2 2026, selling an estimated $64.4K and leaving 3,264 shares worth $1.18M. The position accounts for 0.16% of the portfolio, ranked #98.

Biltmore Family Office first reported a position in AMGN in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.21M in Q1 2026. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Biltmore Family Office held 3,264 shares of Amgen worth $1.18M as of Q2 2026.
  • Biltmore Family Office sold 188 Amgen shares in Q2 2026, an estimated $64.4K.
  • Amgen made up 0.16% of Biltmore Family Office's portfolio in Q2 2026, its #98 holding.
  • Biltmore Family Office first reported a position in Amgen in Q4 2017 and has held it in 35 quarters since.
  • Biltmore Family Office's Amgen position peaked at $1.21M in Q1 2026.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Biltmore Family Office's 13F filing for Q2 2026, filed 12 Aug 2026.